| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10213034 | Atherosclerosis | 2018 | 32 Pages |
Abstract
Circulating PCSK9 concentrations are not associated with the severity of liver steatosis or histological markers of NASH. These data are reassuring regarding the clinical use of PCSK9 inhibitors in cardiovascular diseases.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Matthieu Wargny, Pierre-Henri Ducluzeau, Jean-Michel Petit, Cédric Le May, Sarra Smati, Lucie Arnaud, Matthieu Pichelin, Benjamin Bouillet, Adrien Lannes, Odile Blanchet, Philippe Lefebvre, Sven Francque, Luc Van Gaal, Bart Staels, Bruno Vergès,